Synapse - Works

Results (988)

Phase 1 trial of carfilzomib + melphalan (CarMel) conditioning and autologous hematopoietic stem cell transplantation (AHSCT) for relapsed multiple myeloma (MM)

Meeting Abstract

Costa, L. J.; Landau, H.; Venkata, J. K.; Kang, Y. B.; Koehne, G.; Chung, D. J.; Lendvai, N.; Bentz, T.; Giralt, S. A.
Biology of Blood and Marrow Transplantation (2014)

Fulltext@MSK | Save

Immune reconstitution after autologous stem cell transplantation for multiple myeloma

Meeting Abstract

Chung, D. J.; Pronschinske, K. B.; Shyer, J. A.; Wu, V.; Hassoun, H.; Landau, H.; Lendvai, N.; Lesokhin, A. M.; Koehne, G.; Giralt, S. A.; more...
Biology of Blood and Marrow Transplantation (2014)

Fulltext@MSK | Save

Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma

Journal Article

Postow, M. A.; Yuan, J.; Kitano, S.; Lesokhin, A. M.; Wolchok, J. D.
Methods in Molecular Biology (2014)

Fulltext@MSK | Save

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

Meeting Abstract

Callahan, M. K.; Horak, C. E.; Curran, M. A.; Hollman, T.; Schaer, D. A.; Yuan, J.; Lesokhin, A. M.; Kitano, S.; Hong, Q.; Ariyan, C. E.; more...
Journal for ImmunoTherapy of Cancer (2013)

Fulltext@MSK | Save

Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)

Meeting Abstract

Wolchok, J. D.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Reed, K.; Burke, M. M.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis

Meeting Abstract

Reece, D. E.; Hegenbart, U.; Sanchorawala, V.; Merlini, G.; Palladini, G.; Blade, J.; Fermand, J. P.; Hassoun, H.; Heffner, L.; Pei, L.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

A phase I dose-escalation study evaluating the effects of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed or refractory hematologic malignancies

Meeting Abstract

Lesokhin, A. M.; Gutierrez, M.; Halwani, A. S.; Ansell, S. M.; Armand, P.; Borrello, I.; Segota, Z. E.; Cohen, A. D.; Talpaz, M.; Cattry, D.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

Meeting Abstract

Callahan, M. K.; Horak, C. E.; Curran, M. A.; Hollman, T.; Schaer, D. A.; Yuan, J.; Lesokhin, A. M.; Kitano, S.; Hong, Q.; Ariyan, C. E.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Multiple copies of MLL is the most commonly detected cytogenetic abnormality in newly diagnosed multiple myeloma and may modify disease risk

Meeting Abstract

Landry, C.; Londono, D.; Devlin, S. M.; Lesokhin, A.; Lendvai, N.; Hassoun, H.; Chung, D. J.; Koehne, G.; Jhanwar, S. C.; Giralt, S. A.; more...
Blood (2013)

Fulltext@MSK | Save

Pilot study to evaluate the prevalence of actionable oncogenic mutations in patients with relapsed refractory multiple myeloma

Meeting Abstract

Lesokhin, A.; Gonen, M.; Redling, K.; Lendvai, N.; Hassoun, H.; Landau, H.; Chung, D. J.; Koehne, G.; Patel, M.; Brennan, K. W.; more...
Blood (2013)

Fulltext@MSK | Save